Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults - Nature

Clicks: 146
ID: 272847
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
In a dose-escalation study of the COVID-19 RNA vaccine BNT162b1 in 45 healthy adults, RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titres in sera increased with dose level and after a second vaccine dose.
Reference Key
j.2020naturephase i/ii Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mulligan, Mark J.;Lyke, Kirsten E.;Kitchin, Nicholas;Absalon, Judith;Gurtman, Alejandra;Lockhart, Stephen;Neuzil, Kathleen;Raabe, Vanessa;Bailey, Ruth;Swanson, Kena A.;Li, Ping;Koury, Kenneth;Kalina, Warren;Cooper, David;Fontes-Garfias, Camila;Shi, Pei-Yong;Türeci, Özlem;Tompkins, Kristin R.;Walsh, Edward E.;Frenck, Robert;Falsey, Ann R.;Dormitzer, Philip R.;Gruber, William C.;Şahin, Uğur;Jansen, Kathrin U.;Mulligan, Mark J.;Lyke, Kirsten E.;Kitchin, Nicholas;Absalon, Judith;Gurtman, Alejandra;Lockhart, Stephen;Neuzil, Kathleen;Raabe, Vanessa;Bailey, Ruth;Swanson, Kena A.;Li, Ping;Koury, Kenneth;Kalina, Warren;Cooper, David;Fontes-Garfias, Camila;Shi, Pei-Yong;Türeci, Özlem;Tompkins, Kristin R.;Walsh, Edward E.;Frenck, Robert;Falsey, Ann R.;Dormitzer, Philip R.;Gruber, William C.;Şahin, Uğur;Jansen, Kathrin U.;
Journal Nature
Year 2020
DOI
doi:10.1038/s41586-020-2639-4
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.